Newcells Biotech (Newcastle, UK) has secured a £2 million (approximately €2 270 000) investment to support its ambitious growth plans. The funding will allow the company to expand its current capabilities, accelerating plans to develop and launch new cell-based assays for pre-clinical drug discovery and development.
Founded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced pluripotent stem cells (hiPSC), a technology that is quickly advancing the field of pre-clinical disease modelling, and drug safety evaluation.
Newcells Biotech is focused on incorporating the “best in biology” into cell based assays to create 2-D or 3-D (organoids) formats that deliver models that are better mimics of in vivo physiology. The company has launched a validated assay for kidney transporter and nephrotoxicity measurement. Their development pipeline includes hiPSC based models of the human retina and skin with applications on drug safety assessment, pharmacokinetics and disease modelling.
Newcells Biotech is transforming how innovative drugs and compounds are being developed and is on course to be a major supplier in the global drug discovery market. The discovery of hiPSCs in combination with advances in the understanding of human cell developmental biology has created the conditions for a transformation in pre-clinical science.